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Abstract 
 
Embase and Pubmed were systematically searched for articles addressing the 
neuroprotective properties of phytocannabinoids, aside from cannabidiol and 9-
tetrahydrocannabinol, including 9-tetrahydrocannabinolic acid (9-THCA), 9-
tetrahydrocannabivarin (9-THCV), cannabidiolic acid  (CBDA), cannabidivarin (CBDV), 
cannabichromene (CBC), cannabichromenic acid (CBCA), cannabichromevarin (CBCV), 
cannabigerol (CBG), cannabigerolic acid (CBGA), cannabigerivarin (CBGV), 
cannabigerovarinic acid (CBGVA), cannabichromevarinic acid (CBCVA) cannabidivarinic 
acid (CBDVA) and cannabinol (CBN). Out of 2,341 studies, 31 articles met inclusion criteria. 
CBG (range 5 mg.kg-1 to 20 mg.kg-1) and CBDV (range 0.2 mg.kg-1 to 400 mg.kg-1) displayed 
efficacy in models of Huntington’s disease and epilepsy. CBC (10-75 mg.kg-1), 9-THCA (20 
mg.kg-1) and 9-THCV (range 0.025-2.5 mg.kg-1) showed promise in models of seizure and 
hypomobility, Huntington’s and Parkinson’s disease. Limited mechanistic data showed CBG, 
VCE.003, VCE.003.2 and 9-THCA mediated some of their effects through PPARy, but no 
other receptors were probed. Further studies with these phytocannabinoids, and their 
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Introduction 
 
According to the World Health Organisation (WHO), neurodegenerative diseases will be the 
second most prevalent cause of death by 2040 (Gammon, 2014). The cellular mechanisms of 
these diseases typically overlap with neuronal dysfunction and neuronal cell death being a 
common thread, regardless of definitive clinical presentations. Typically, neurodegenerative 
diseases are categorised as amyloidoses, which includes Alzheimer’s disease and British 
familial dementia; synucleinopathies, which includes lewy body disorders such as 
Parkinson’s; and proteinopathies, which includes amyotrophic lateral sclerosis (ALS) and 
tauopathies (Kovac, 2018). Other common neurological disorders include epilepsy and 
stroke, characterised by recurring, unprovoked seizures and vascular pathology respectively. 
Recently, stroke was re-classified as a neurological disease by the International Classification 
of Disease (ICD) 11, highlighting that whilst strokes predominantly derive from vascular 
origin, the neurological consequences are often severe (Shakir, 2018).  
 
Current treatments for neurodegenerative and neurological conditions are often limited and 
usually rely on managing symptoms rather than making a significant impact on delaying 
disease progression (Kiaei, 2013). For example, Huntington’s disease is managed with 
tetrabenazine (TBZ) 75-200 mg per day to alleviate chorea (involuntary movement), but 
because it acts as a vesicular monoamine transporter (VMAT) inhibitor, interfering with both 
serotonin and dopamine degradation, patients can develop neuropsychiatric symptoms 
along with other side effects (Hayden et al., 2009; Kaur et al., 2016; Wyant, Ridder and 
Dayalu, 2017). Other first line treatments, for example L-Dopa in Parkinson’s disease, often 
cause side effects and do not delay disease progression. Finally, cholinesterase inhibitors 
such as donepezil are only minimally effective in improving cognition for the treatment of 
Alzheimer’s disease. In light of this, there is clearly an urgent need to develop new therapies 
with more tolerable side effect profiles to combat these debilitating conditions and increase 
the quality of life of the aging population. 
 
Over 120 different phytocannabinoids have been isolated from Cannabis Sativa (ElSohly and 
Gul, 2015). Of these, 9- tetrahydrocannabinol (9-THC) and cannabidiol (CBD) are the most 
abundant and widely studied. 9-THC is responsible for the psychoactive effects of cannabis, 
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which are mediated through the cannabinoid type 1 receptor (CB1) Pertwee 2008. 9-THC 
also interacts with other targets including transient receptor potential (TRP) channels, the 
orphan G-protein receptor, GPR55, and peroxisome proliferator-activated receptors (PPARs) 
(Pertwee and Cascio, 2015). CBD has also been shown to modulate a plethora of 
pharmacological targets including 5-HT1A, PPARγ and TRPV1, but has no psychotropic effects 
because it does not activate central CB1 receptors (reviewed in Ibeas Bih et al., 2015 and 
Russo, E. B., & Marcu, J. 2017). Interaction with these targets has given CBD status as a 
neuroprotectant, anti-inflammatory agent and antioxidant (Fernandez-Ruiz et al., 2012 and 
Maroon et al., 2018). These features, along with its favourable safety profile in humans 
(World Health Organization, 2017; Millar et al., 2019) has made CBD, in many respects, a 
more desirable drug candidate than 9-THC. CBD has shown promise in several animal 
models of neurodegeneration as well as clinical trials for Parkinson’s, Alzheimer’s and 
amyotrophic lateral sclerosis (ALS) (Iuvone et al., 2009). Furthermore, a CBD: 9-THC (1:1) 
product is currently licenced by GW Pharmaceuticals under the brand name Sativex® to 
treat pain and spasticity associated with multiple sclerosis (MS), and Epidiolex® (pure CBD) is 
licensed to treat Lennox-Gastaut syndrome and Dravet syndrome, which are severe forms of 
childhood epilepsy. Other cannabis-based medicines (CBMs) are also under development: 
GW pharmaceuticals has four compounds (structures are not disclosed) in the pipeline for 
neurological conditions including glioblastoma, schizophrenia and neonatal hypoxic-
ischaemic encephalopathy (GW Pharmaceuticals, 2019).  
 
Phytocannabinoids are highly unique compounds, they are promiscuous, modulating a 
range of pharmacological targets as well as exhibiting high antioxidant capability due to 
their phenolic structures and the presence of hydroxyl groups (Hampson et al., 1998; 
Yamaori et al., 2011; Borges et al., 2013). These features, along with their lipophilicity and 
ability to act as anti-inflammatory agents makes them desirable therapeutic candidates for 
the treatment of CNS disorders, as they can effectively cross the blood-brain barrier (BBB), 
modulate the immune response and overall target the many facets of neurodegeneration 
(Deiana et al., 2012). These characteristics have been well established for 9-THC and CBD 
but are less known for some of the minor constituents of the plant and in order to 
understand the full therapeutic potential of cannabis sativa, the pharmacology of the lesser-
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known components of the plant should be elucidated (Turner et al., 2017). Given the wide-
ranging neuroprotective effects of 9-THC and CBD already established, it is not unfounded 
to suggest other phytocannabinoids may exhibit similar or more potent neuroprotective 
properties. Therefore, the aim of this systematic review was to collate all available data on 
the neuroprotective effects of 9-tetrahydrocannabinolic acid (9-THCA), 9-
tetrahydrocannabivarin (9-THCV), cannabidiolic acid  (CBDA), cannabidivarin (CBDV), 
cannabichromene (CBC), cannabichromenic acid (CBCA), cannabichromevarin (CBCV), 
cannabigerol (CBG), cannabigerolic acid (CBGA), cannabigerivarin (CBGV), 
cannabigerovarinic acid (CBGVA), cannabichromevarinic acid (CBCVA) cannabidivarinic 
acid (CBDVA) and cannabinol (CBN). These phytocannabinoids were selected based on their 
abundance in the plant, ease of synthesis, efficacy in other fields (e.g as anticancer agents or 
treatments for inflammatory bowel disease) and similarities in their structure to CBD and 
9-THC (which have already shown promise as a neuroprotectants and displayed safety in 




Data sources and search strategy 
 
An electronic search was conducted using the search engines PubMed and Embase from its 
inception to June 2019. This was carried out in accordance with the PRISMA (Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses) guidelines (Moher D, Liberati A, 
Tetzlaff J, 2009; Tóth et al., 2010; Shamseer et al., 2015) Search terms included 9-
tetrahydrocannabinolic acid, 9-tetrahydrocannabivarin, cannabidiolic acid, cannabidivarin, 
cannabichromene, cannabichromenic acid, cannabichromevarin, cannabigerol, 
cannabigerolic acid , cannabigerivarin, cannabigerovarinic acid, cannabichromevarinic acid, 
cannabidivarinic acid and cannabinol (and their corresponding abbreviations), 
phytocannabinoids, neurovascular unit, pericytes, neurons, astrocytes, human brain 
microvascular endothelial cells, brain, neuroinflammation, hyperexcitability, 
neurodegeneration, Huntington’s, Alzheimer’s, Parkinson’s, epilepsy and stroke. Two 
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independent reviewers carried out the searches by November 2019 and the reference lists 
of the final papers were hand searched for any additional studies. 
 
Eligibility and exclusion criteria 
 
Conference abstracts and review articles were excluded. No restrictions were applied to 
type of study, publication year, or language. Inclusion criteria were as follows: an original, 
peer reviewed article that involved the application of emerging phytocannabinoids in an in 
vivo or in vitro model of neurodegeneration or neuronal damage. Studies that looked at CBG 
derivatives VCE-003 or VCE-002.3 were also included because current research is targeted at 
these compounds due to their increased affinity for PPARγ.  Studies that assessed CBD, 9-
THC, 9-THC: CBD 1:1 (Sativex®) or similar combination of phytocannabinoids (i.e different 
ratios of phytocannabinoids) were excluded from this review. After duplicates and irrelevant 
articles were removed, the full text was obtained for the remaining articles and studies were 
examined for data regarding 9-THCA, 9-THCV, CBDA, CBDV, CBC, CBCA, CBCV, CBG, CBGA, 
CBGV, CBGVA, CBCVA, CBDVA and CBN application in an in vitro and/or in vivo model of 
neuroprotection or neuronal damage. Dose and route of administration were extracted 
from in vivo studies and where possible range and average were calculated. If studies 
reported mechanistic data, this was also described in the results section. 
Results 
  
The preliminary search retrieved 2,341 studies, which after duplicates were removed left 
1,851. A total of 107 cannabinoid studies were retrieved, once exclusion criteria were 
applied, 26 articles were considered to be potentially relevant and their full texts obtained. 
After additional screening (including reviewing reference lists for any potential studies) 28 
studies were included in this review, see figure 1. Table 1a summarises the in vitro data 
included in this review and table 1b summarises the in vivo data. Within the 28 studies, the 
neuroprotective models were epilepsy (n=7), Huntington’s disease (n=6), Parkinson’s (n=4), 
amyloid lateral sclerosis (ALS) (n=3), neuroprotection (not disease specific, n=2), multiple 
Sclerosis (MS) (n=1), Rett Syndrome (n=2), neuroinflammation (n=1), Alzheimer’s (n=1), and 
oxidative stress (n=1). Fifteen papers studied CBG or its derivatives, 5 studies used CBN, 8 
studies used CBDV and 4 studies used CBC. Only 2 studies used 9-THCV and 3 used 9-
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THCA. CBDA was only included in one study. No data on the neuroprotective effects of, 
CBGA, CBGV, CBCA, CBCV, CBCVA, CBGVA, or CBDVA were identified. Figure 2 depicts some 
of the minor phytocannabinoids structures with CBD and 9-THC for reference and table 2 
summarises the neurological conditions for which emerging cannabinoids have shown 
therapeutic potential. 
 
Cannabigerol (CBG) and its derivatives 
 
Nine studies included in vitro data and 8 included in vivo data on CBG and its derivatives 
which are formed by the oxidation of CBG (Carrillo-Salinas et al., 2014; Díaz-Alonso et al., 
2016; García et al., 2018). VCE-003 and VCE-003.2 have displayed increased affinity for 
PPAR, thus maintaining their anti-inflammatory properties whilst having little affinity for 
CB1 and CB2  (VCE-003 Ki >40 µM for CB1 and >1.76 µM CB2 (Granja et al., 2012) and VCE-
003.2 Ki >40 µM for both CB1 and CB2 (García et al., 2018).  All studies except one, reported a 
positive effect of CBG, VCE-003 or VCE-002.3 vs control in the disease model being studied. 
In an in vivo 3-nitropropionic acid (3-NP) model to induce Huntington’s disease, CBG (10 
mg.kg-1 per day i.p) significantly attenuated the upregulation of COX-2, iNOS, IL-6 and TNF-α 
(Valdeolivas et al., 2015). CBG treatment also prevented 3-NP-induced neuronal loss, 
recovered catalase, superoxide dismutase and glutathione versus control, as well as 
downregulating genes that were directly associated with Huntington’s disease including 
sgkl, Cd44 and normalised huntingtin associated protein-1. Aggregation of mutant 
Huntingtin protein was diminished and motor deficits such as hindlimb clasping and 
dystonia and general locomotor activity were also improved (Valdeolivas et al., 2015). Hill et 
al., (2014) assessed the anti-convulsant potential of CBG (50-200 mg.kg-1 i.p) when 
administered prior to the initiation of pentylenetetrazole (PTZ) seizures, however despite 
being able to block Nav channel activity CBG had no effect on seizure severity. No 
antagonist experiments were conducted in these studies, but Valdeolivas et al., (2015) did 
show that CBG dose-dependently activated PPAR in cultured striatal cells (WT and mutant 
huntingtin; supplementary data). Four studies reported that the CBG derivatives VCE-003 (5 
mg.kg-1i.p) and VCE-003.2 (10 mg.kg-1oral/i.p) successfully reduced immune cell activation in 
macrophages, microglia and infiltrating neutrophils in models of EAE (to model MS), 
Huntington’s and LPS induced Parkinson’s disease (PD) (Carrillo-Salinas et al., 2014; Díaz-
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Alonso et al., 2016; García et al., 2018; Aguareles et al., 2019). In the in vivo PD model, 
García et al., (2018) found that PPARγ antagonist T0070907 (5 mg.kg-1) blocked VCE-003.2 
mediated decreases in TNF-, IL-1  and iNOS mRNA levels, but no other antagonists were 
investigated. In a follow up study by the same group, 20 mg.kg-1 (but not 10 mg.kg-1) oral 
VCE-003.2 promoted a trend towards recovery in the basal ganglia of LPS lesioned mice and 
was associated with decreases in IL-1 gene expression, lysosomal-associated membrane 
protein-1 (LAMP-1) and glial fibrillary acidic protein (GFAP) immunostaining (Burgaz et al., 
2019). Orally dosed VCE-003.2 (10 mg.kg-1) promoted neurogenesis in mice subjected to 
mutant Huntingtin expression in a Huntington’s disease model (Aguareles et al., 2019). In 
another model of Huntington’s disease VCE-003.2 (10 mg.kg-1 i.p) prevented neuronal loss, 
indicated by increases in Nissl and NeuN staining and at the same dose improved RotaRod 
performance and reduced astrogliosis in mice, measured by attenuated levels of GFAP and 
ionized calcium binding adaptor molecule 1 (Iba-1) (Díaz-Alonso et al., 2016). Rodrigueuz-
Cueto et al., (2018) found that VCE-003.2 10 mg.kg-1 i.p successfully improved 
neuropathological deterioration and normalised CB2 receptor and IL-1β levels, in an 
experimental model of ALS, but again no mechanisms of action were probed.  
 
In vitro, Schubert et al., (2019) reported that CBG (100 nM) prevented MC65 neurons from 
accumulating toxic amyloid beta (A) protein in an Alzhiemer’s disease model. CBG also 
preserved neuronal trophic factors in primary rat cortical neurons (EC50 1.5 M) and 
prevented oxytosis in mouse HT22 hippocampal nerve cells (EC50 1.9 M). Although no 
mechanisms were explored in this study, neither MC65 neurons nor HT22 cells express CB1 
or CB2, thus authors concluded that these effects were mediated independently of these 
receptors. In N2a cells, VCE-003.2 (10, 25 µM) prevented excitotoxicity induced by 
glutamate and in models of LPS induced PD and ALS (García et al., 2018; Rodríguez-Cueto et 
al., 2018). Similarly, VCE-003 (0.1-25 μM) dose dependently protected neuronal cells in a 
model of multiple sclerosis (MS), while VCE-003.2 (500 nM) promoted neuronal 
differentiation when dosed for 21 days in an in vitro model of Huntington’s disease, but no 
antagonist experiments were conducted to explain these effects  (Granja et al., 2012; 
Aguareles et al., 2019). In a model of neuroinflammation, pre-treatment with CBG (7.5 M) 
improved viability in cells treated medium from LPS stimulated macrophages and while 
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authors reported that CBG treatment resulted in PPARγ downregulation, no direct 
mechanistic probing was conducted (Gugliandolo et al., 2018). Granja et al., (2012) and 
Carillos-Salinas et al., (2014) found that treatment with VCE-003 (1, 2.5 M and 1, 10,25 
M) blocked the secretion of a number pro-inflammatory mediators including IL-6, TNF-, 
IL-1 and MIP-1 in macrophages and primary microglia. VCE-003.2 also attenuated TNF- 
and L-1 secretion but from BV2 mouse microglial cells (5 M) and astroglial cells (1, 5 M) 
(Díaz-Alonso et al., 2016; García et al., 2018; Rodríguez-Cueto et al., 2018). Díaz-Alonso et 
al., (2016) and Concepción García et al., (2018) deduced that VCE-003.2 did not mediate its 
protective effects via CB1/CB2 due to poor binding affinity (Ki >40 µM) and both groups 




All in vivo cannabidivarin (CBDV) studies evaluated the anti-epileptic properties of the 
compound in models of Rett syndrome and MES seizures (Hill et al., 2012, 2013; Amada et 
al., 2013; Vigli et al., 2018; Zamberletti et al., 2019). Doses in these studies ranged from 0.2 
to 400 mg.kg-1 per day in rodents with efficacy in reducing tremors was observed between 
2-200 mg.kg-1 per day. Two studies reported that 200 mg.kg-1 i.p CBDV significantly 
decreased PTZ seizure severity and mortality in rats (A. J. Hill et al., 2012; T. D. M. Hill et al., 
2013). Hill et al., (2012) found that 90% of animals remained seizure free at a dose of 200 
mg.kg-1 CBDV i.p per day, however lower concentrations of CBDV were ineffective (0.2 
mg.kg) and CBDV had no effect on the severity of pilocarpine convulsions at any tested 
concentration (50-200 mg.kg-1 day). CBDV (400 mg.kg-1 oral gavage) suppressed PTZ seizures, 
significantly decreasing seizure severity (P<0.05) but had no effect on expression of epilepsy 
related genes (Amada et al., 2013). Another study reported that 20 mg.kg-1 i.p CBDV dosed 
for 14 days improved brain weight in Rett syndrome (RTT) mice vs WT mice, but had no 
effect on neurotrophin levels (Vigli et al., 2018).  None of the above in vivo studies 
conducted antagonist experiments to elucidate CBDVs anticonvulsant effects. 
 
In HEK293 cells transfected with TRPV1, 2 and 3 channels, CBDV caused a concentration-
dependent bidirectional current at TRPV1 similar to capsaicin and capsazepine (TRPV1 
antagonist) blocked this effect. Furthermore, 5'-Iodoresiniferatoxin (5'-IRTX), a selective 
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TRPV1 antagonist counteracted the effect of CBDV in the duration but not amplitude of 
neuronal burst. These data suggest that CBDV acts as an agonist at TRPV1, but some of 
CBDVs effects are mediated independently of this receptor. However, no other antagonists 
were tested to establish which receptors were responsible for CBDVs other effects (Iannotti 
et al., 2014). Hill et al., (2012) reported that CBDV (10 and 100 M) decreased the amplitude 
and duration of local field potentials (LFPS) in hippocampal brain slices, with an anti-
epileptiform effect observed in the CA1 region (100 µM). CBDV also showed efficacy in an in 
vitro model of Alzheimer’s disease (AD), preventing oxytosis and energy loss in HT22 cells 
(EC50 1.1 µM and 90 nM respectively), as well as reducing Aβ toxicity (EC50 100 nM) and 
trophic withdrawal (EC50 350 nM), however no mechanistic data were reported to 
determine how these effects were mediated (Schubert et al., 2019).  
Cannabichromene (CBC) 
 
In a model of electroshock seizure, CBC (10-75 mg.kg-1 i.p per day) significantly depressed 
motor activity during the first 10-minute interval, but subsequently only the highest dose 
was effective (Davis & Hatoum, 1983). In vitro Shinjyo & Di Marzo, (2013) found that 1 M 
CBC increased viability of adult nestin positive neuronal stem cells when applied in medium 
without growth factors (B27 medium), by inducing extracellular signal-regulated kinase 
(ERK) phosphorylation. No antagonist data was presented in these studies. 
Cannabinol (CBN) 
 
Only one in vivo study assessed CBN (5 mg.kg-1 per day) in an SOD1 model of Amyotrophic 
lateral sclerosis (ALS). CBN delayed motor abnormalities at day 17 in the chronic treatment 
regimen, vs vehicle control, but disease progression was not affected (Weydt et al., 2005). In 
a model of Huntington’s disease, Aiken, Tobin, & Schweitzer, (2004) found that CBN reduced 
lactate dehydrogenase (LDH) activity in PC12 cells (20 and 100 M), but authors did not 
probe the mechanism of this effect. CBN displayed potent antioxidant activity in primary 
cerebral granule cells under oxidative stress conditions, however no antagonist data was 
presented on this cannabinoid (Marsicano et al., 2002).  
9-THCV  
 
Male Sprague Dawley rats and CB2 knockout mice were dosed with 2 mg.kg-1 per day 9-
THCV over a period of 14 days in a model of PD, induced by 6-hydroxydopamine (6-OHDA) 
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or lipopolysaccharide (LPS) (García et al., 2011). 9-THCV reduced slow motor movements 
induced by 6-OHDA and enhanced mean velocity of movement with a potency similar to 
rimonabant. Chronic 9-THCV dosing reduced microglial activation and preserved 
nigrostriatal dopaminergic neurons after 6-OHDA application and in the LPS model of PD, 
9-THCV preserved tyrosine hydroxylase positive neurons, mirroring the effects of CB2 
agonist HU-308. Thus, authors speculated that 9-THCV mediated at least some of its effects 
in the LPS model via CB2(García et al., 2011). Authors also reported that 2 mg.kg-1 9-THCV 
blocked the effects of the CB1 agonist, CP55,940, suggesting it acts as an antagonist at this 
receptor, however no data was presented assessing if 9-THCV’s antagonistic properties at 
CB1 mediated its protective effects in the 6-OHDA or LPS models of PD. Hill et al., (2010) 
studied 9-THCV in a seizure model induced by 80 mg.kg-1 PTZ and found that at a dose of 
0.25 mg.kg-1 i.p 9-THCV, with 33% of animals having a complete absence of seizures. 
Although no direct mechanistic probing was investigated, receptor binding assays were 
performed on rat cortical membranes and 9-THCV was found to act as a CB1 ligand (CB1 
Ki∼290 nM; [3H]SR141716A displacement but no agonist stimulation using [35S] GTPγS 




In an acute 3-NPA model of Huntington’s disease, Nadal et al., (2017) observed a significant 
improvement in hindlimb dystonia (uncontrollable hindlimb muscle contraction) and 
locomotor activity in male, C57BL/6 mice treated with 9-THCA (20 mg.kg-1 per day i.p). 9-
THCA also prevented astrogliosis, microgliosis and attenuated the upregulation of pro-
inflammatory mediators induced by 3-NPA, these effects were blocked when mice were co-
administered with PPARγ antagonist T0070903 (with the exception of IL-6) (Nadal et al., 
2017). In vitro, N2a cells infected with the huntingtin polyQ repeats resulted in toxicity, 
which was significantly reduced by treatment with ∆9-THCA, as well as decreased expression 
of inflammatory mediators: TNF-alpha, iNOS, IL-6, COX-2. 9-THCA also improved neuronal 
viability post serum deprivation and this effect was prevented by GW9662, a PPARy 
antagonist. No other antagonists were used in this study (Nadal et al., 2017). 
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9-THCA (0.01-10 M) displayed no pro-survival effect on dopaminergic neurons but had a 
significant, positive effect on cell count (123%) when compared to the control in an in vitro 
model of PD (Moldzio et al., 2012).  
Discussion 
 
To our knowledge, this is the first systematic review on the neuroprotective effects of 
lesser-known minor phytocannabinoids in various models of neurological disease. Data 
obtained from our search revealed that CBG, VCE.003, VCE.003.2 and CBDV were the most 
promising candidates as neuroprotectants, while 9-THCV, 9-THCA, CBC and CBN have 
limited but encouraging data as neuroprotectants. CBG, VCE.003, VCE.003.2 and 9-THCA 
mediated their neuroprotective effects at least in part by the nuclear receptor PPARy. CBDV 
was found to mediate some of its antiepileptic effects via TRPV1 and 9-THCV was found to 
be a CB1 ligand and a possible CB2 agonist, but no experiments were conducted to establish 
whether its neuroprotective action was mediated by CB1 or CB2. No other receptors were 
investigated, and no studies assessed the neuroprotective potential of CBDA, CBGA, CBGV, 
CBCV, CBGVA, or CBDVA.  
 
CBG was first isolated in 1964 by the same group that reported the structure of 9-THC 
(Gaoni and Mechoulam, 1964), it possesses antioxidant and anti-inflammatory properties, 
whilst displaying no psychotropic effects as it is a poor CB1 agonist (Gauson et al., 2007; 
Rosenthaler et al., 2014; Navarro et al., 2018). CBG is a partial agonist towards CB2, a potent 
α2-adrenoceptor (A2A) agonist (EC50 0.2 nM) and a moderate 5-HT1A receptor antagonist, as 
well as interacting with various TRP isoforms including TRPV1 and 2 (Cascio et al., 2010; De 
Petrocellis et al., 2012). Studies included here show that these compounds have significant 
anti-inflammatory effects, including attenuating cytokine release and decreasing the 
activation of immune cells, an effect observed in both in vitro and in vivo models.  
 
CBG and its derivatives were particularly effective in models of Huntington’s disease, 
targeting multiple facets of the disease including gene expression, easing motor symptoms, 
reducing microglial activation and attenuating the inflammatory response.  Huntington’s 
disease pathophysiology, like other neurodegenerative disorders, exhibits uncontrolled 
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microglial activation which is a key part of the neuroinflammatory response. In early stages 
of HD, positron emission tomography (PET) imaging has revealed marked microglial 
activation, which was correlated with impairments of neuronal activity (Tai et al., 2007). 
Microglial activation along with increases in pro-inflammatory mediators have also been 
detected in post-mortem HD brains (Palpagama et al., 2019). Interestingly, microglial 
mediated neuroinflammation was suppressed with the activation of CB2 receptors (Ehrhart 
et al., 2005). However, given VCE-003 and VCE.003.2’s protective effects were likely to be 
CB1 and CB2 independent, their effects on microglial activation are likely to be via a different 
mechanism, possibly through the activation of PPARy which has an important role in 
regulating the inflammatory response, especially in the CNS (reviewed in Bright et al., 2008 
and Villapol., 2018). It is also worth noting that microglial activation can be protective, 
preserving neurons by secreting anti-inflammatory cytokines such as IL-4 and IL-10 as well 
as various trophic factors (Reviewed in Le, Wu and Tang, 2016 and Pöyhönen et al., 2019). In 
line with these observations, there effectively needs to be a balancing act between enabling 
some degree of microglial activation to protect neurons, whilst limiting their overactivation 
which would ultimately lead to damage. Given that HD symptoms are currently managed 
using VMAT inhibitors (TBZ) to decrease levels of monoamines, it would be useful to assess 
whether CBG and its derivates have any efficacy as VMAT inhibitors, or whether their 
protective effects in models of Huntington’s disease are independent of this mechanism. If 
the latter is the case, future studies should investigate low dose VMATs (to minimise 
neuropsychiatric side effects) together with CBG or its derivatives as an adjuvant therapy to 
assess if there is a cumulative protective effect of these compounds. 
 
Long-term dose tolerability and a lack of accumulation in tissue are both essential features 
of neuroprotective agents as these drugs are typically taken for life after disease onset. In a 
study conducted by Deiana et al., (2012), CBG was found to have similar PK profiles in rats 
and mice but exhibited slower brain penetration in mice. Both animals also had higher 
concentrations of CBG following i.p injection compared to oral administration, but 
interestingly in rats this did not equate to higher concentrations in brain tissue (Deiana et 
al., 2012). In our review, CBG, VCE-003 and VCE.003.2’s dosing was well tolerated and 
ranged from just 3 days to 10 weeks with two studies dosing CBG orally vs 7 studies dosing 
intraperitoneally. Whilst Diena et al., (2012) reported that animals tolerated CBG 
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administration better via i.p rather than orally, in humans, i.p dosing is not a viable means of 
regular administration and all drugs given orally have a larger side effect profile. Moreover, 
patients receiving certain oral therapies for neurological conditions, such as levodopa for 
Parkinson’s, must also take medications to minimise peripheral effects (Fahn, 2008). 
Therefore, dose formulation and route of administration for these compounds should be 
carefully assessed based on thorough ADME profiling and feasibility of long-term dosing. 
 
CBG exhibited positive effects in two Huntington’s disease models, despite one study 
administering the compound orally and the other by i.p. Of note, CBD has already been 
trialled in Huntington’s disease patients, CBD (10 mg.kg-; 700 mg average daily dose) was 
dosed for 6 weeks, which resulted in a consistent plasma level of 5.9-11 ng.mL and once 
treatment had stopped, elimination was between 2 and 5 days, suggesting CBD does not 
accumulate and remain in plasma longer than 5 days in Huntington’s disease patients 
(Consroe et al., 1991). Future studies should elucidate whether CBG and its derivatives 
display efficacy in humans and clarify whether their activation of PPARy corresponds to their 
neuroprotective properties and if other receptors are involved. More data is also needed on 
CBGs PK profile in older mice and larger mammals and to establish whether it exhibits a 
similar elimination to CBD in humans. These factors would aid in the translation of this 
compound as a treatment for neurodegenerative conditions. 
 
Cannabidivarin (CBDV) is a structural analogue to CBD, with the molecule shortened by two 
methylene bridges (Vollner, L., Bieniek, D., and Korte, 1969; Morales, Hurst and Reggio, 
2017). From our search, in vivo studies consistently reported 200 mg.kg-1 i.p CBDV having 
anti-epileptic effects and a 400 mg.kg-1 oral dose also showing promise. Like CBD, CBDV is a 
agonist at TRPV1/2 and TRPA1, and an antagonist at TRPM8, which may explain similarities 
in their neuroprotective properties, particularly CBDV’s action as an agonist at TRPV1 (Scutt 
and Williamson, 2007; De Petrocellis et al., 2011; Iannotti et al., 2014). In our review, studies 
showed that CBDV did not affect neurotrophic levels or epilepsy related gene expression, 
thus it can be assumed that CBDV mediates its protective effects independent of these 
(Amada et al., 2013; Vigli et al., 2018). Deiana et al., (2012) reported that CBDV was rapidly 
absorbed in mice and rats but there was a higher drug concentration in plasma and brain 
following oral treatment in rats compared to mice. Furthermore, whilst i.p injection resulted 
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in similar PK profiles in the two species, brain concentrations in rats were higher. This brings 
into question the differences in the amount of CBDV delivered to the brain in the studies 
conducted in mice vs rats presented in this review and whether this influenced study 
outcomes. Only two studies reported chronic CBDV dosing both in models of Rett syndrome, 
highlighting the need for future studies to assess the long-term tolerability of CBDV as an 
anti-epileptic agent and how different species exhibit different bioavailability of this 
compound, as these will both affect CBDVs translatability to humans. 
 
Although out of the scope of this review, it is worth noting that CBDV has already been 
trialled as an anti-convulsant by GW Pharmaceuticals in a phase 2a, placebo-controlled study 
of 162 adult patients (clinical trial number: NCT02369471/ NCT02365610). The drug 
GWP42006 (which features CBDV as its main ingredient) was dose titrated (over two weeks) 
up to an 800 mg twice daily dose for a 6 week stable treatment period, however focal 
seizures were inadequately controlled with this dose and GWP42006 displayed no difference 
in efficacy to the placebo control group (Schultz, 2018). Whilst this may cast doubt on the 
translatability of the evidence presented in this review, it is worth highlighting that the 
maximum dose in humans from the GW study would be considerably less than if the same 
dose regimens as the in vivo studies were followed for a 60 kg human. Furthermore, Morano 
et al., (2020) speculated that CBDVs inability to control seizures was in part due to an 
extremely high response from the placebo group and that the use of purified CBDV may have 
also influenced the study outcome. Therefore, it is important to exercise caution when 
extrapolating the findings from the in vitro and vivo data presented here and what doses 
may constitute as effective in clinical trials. 
 
Cannabichromene (CBC) was first isolated in 1966 by Gaoni and Mechoulam and is a non-
psychotropic cannabinoid that does not interact with CB1 (Gaoni and Mechoulam, 1966). 
CBC is an agonist at CB2 and TRP channels, acting potently at TRPA1 as well as displaying 
some activity at TRPV3 and TRPV4 (De Petrocellis et al., 2008, 2011; de Petrocellis et al., 
2012; Cascio and Pertwee, 2015; Udoh et al., 2019). CBC (0.001–1 µM) exhibited promising 
anti-inflammatory effects in an in vitro model of colitis, decreasing LPS increased nitrite 
levels and attenuating INF-γ and IL-10 secretion in peritoneal macrophages (Romano et al., 
2013). More recently CBC acted as a CB2 agonist in AtT20 cells transfected with CB2 and was 
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confirmed by application of CB2 antagonist AM630, which blocked CBCs effects (Udoh et 
al.,2019). We found only two papers related to neuroprotective effects of CBC; in vivo CBC 
suppressed motor activity while in vitro CBC improved viability of neural stem cells (Davis 
and Hatoum, 1983; Shinjyo and Di Marzo, 2013). CBCs anti-inflammatory effects may 
translate to this compound acting as a neuroprotectant as inflammation and overactivation 
of the immune response is an important feature in neurodegenerative conditions. Thus, 
future research should assess this compound in neuro-inflammatory conditions where it 
may have potential. 
 
Cannabinol (CBN) is an oxidative product of ∆9-THC and was the first cannabinoid to be 
discovered and isolated (Wood, Spivey & Easterfield., 1899). Like ∆9-THC it has been shown 
to activate CB1 (Ki 211.2 nM) but with lower potency, as well as acting as an agonist at 
TRPV2 (Rhee et al., 1997; Russo and Marcu, 2017). CBN (1 mg/mL) was recently shown to 
reduce mechanical sensitization and sensitivity of afferent muscle fibers in an in vivo model 
of myofascial pain, but no mechanism of action was investigated (Wong and Cairns, 2019). 
From our search, limited data showed that CBN decreased cell damage and acted as a 
potent antioxidant in a cell-based Huntington’s disease model (Aiken et al., 2004). CBNs 
activity as an antioxidant is a characteristic feature of cannabinoids, which as previously 
mentioned, is thought to be due to the presence of phenolic ring and carboxyl moieties, as 
well as the ability to increase antioxidant defences. CBD has already shown extensive 
antioxidant properties, including increasing the levels and activity of antioxidants, capturing 
reactive oxygen species (ROS) and transforming them into less active forms, as well as 
activating nuclear erythroid 2-related factor (NrF2) which governs the transcription of  many 
antioxidant genes (Reviewed in Atalay, Jarocka-karpowicz and Skrzydlewskas, 2020). 
Oxidative stress is a key feature of neurodegenerative disorders including PD and AD. In 
Alzheimer’s disease, Aβ deposits contain a significant number of binding sites for biometals 
(zinc, copper, iron) which have been shown to contribute to oxidative stress in AD patients 
(Kozlowski et al., 2009; Huang, Zhang and Chen, 2016). Furthermore, AD patients have 
decreased levels of antioxidant enzymes and increased products of oxidative stress, such as 
peroxidised lipids and oxidised proteins in brain tissue (Kim et al., 2006; Sultana et al., 
2011). Also, large amounts of ROS are generated by reactive microglial cells, with studies 
showing superoxide produced by microglia directly contributing to the death of 
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dopaminergic neurons in PD (Hernandes, Café-Mendes and Britto, 2013). It is clear that 
more information is needed on the pharmacology of CBN, especially its antioxidant 
potential. Moreover, the ability of CBDV, CBG, CBC and CBN to reduce Aβ deposits in vitro is 
also noteworthy and will be of interest to examine the antioxidant and anti-inflammatory 
potential of these compounds in in vivo AD models and whether these compounds act 
through similar mechanisms to CBD. 
  
∆9-THCV is a homologue of ∆9-THC differing by just a propyl side chain and studies have 
suggested that ∆9-THCV acts as a CB1 receptor agonist, sharing similar properties to ∆9-THC 
albeit with less potency (Gill, Paton and Pertwee, 1970; Pertwee, 2008). They exhibit 
similarities in their in vivo effects such as inducing catalepsy in mice and ∆9-THC-like effects 
in humans (Gill, Paton and Pertwee, 1970; Hollister, 1974). We found two studies where ∆9-
THCV showed promise as an anti-epileptic agent and protected neurons in two models of 
PD, while García et al., (2011) suggested ∆9-THCV mediated some of its protective effects by 
acting at CB1 and CB2,  ∆9-THCVs mechanism of action was largely unexplored (Hill et al., 
2010; García et al., 2011). In an earlier study, Thomas et al., (2005) found that ∆9-THCV 
displaced [3H]CP55940 from specific sites in mouse brain and CHO-hCB2 cell membranes (Ki 
values 75.4 nM and 62.8 nM respectively) and along with data from GTP𝛾S-binding  
experiments authors concluded ∆9-THCV acted as a CB1 and CB2 receptor antagonist. Other 
groups have shown ∆9-THCV can block CB1 activity in murine cerebellar slices and at 5.8 M 
increase GABA release from neurons, sharing the same properties as AM251, a CB1 receptor 
antagonist (Ma et al., 2008; Pertwee, 2008). Thus, whilst there is evidence to suggest ∆9-
THCV mediates some of its protective effects via CB1 and CB2, the data remains largely 
unclear, and there is also a lack of investigation into the potential of ∆9-THCV to act at other 
known cannabinoid targets.  
 
Microglial activation and the presence of neuroinflammatory factors are well known 
characteristics of Parkinson’s and well documented amongst PD sufferers (Mogi et al., 1994; 
Qian et al., 2011). Moreover, studies have demonstrated that microglial over-activation 
leads to deleterious effects and the exacerbation of the immune response, especially the 
release of pro-inflammatory mediators. Like CBG derivative VC-003.2, ∆9-THCV reduced 
microglial activation, inducing a protective effect by dampening the immune response. 
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Studies have already demonstrated CBDs ability to modulate the immune response by 
acting an agonist of PPARγ and altering nuclear factor-κB (NFκB) signalling, which is 
upregulated in both microglia and astrocytes of PD patients. Furthermore, activation of 
PPARγ  leads to inhibition of NFκB signalling and decreases mRNA levels of proinflammatory 
mediators TNF-a, IL-1β, IL-6 and iNOS (Vallée et al., 2017). Therefore, it would be of interest 
to determine whether ∆9-THCVs ability to reduce microglial activation is carried out by the 
same mechanism as CBD, involving the activation of PPARγ. 
 
Limited pharmacokinetic data on 9-THCV has shown it exhibits rapid absorption in rats and 
mice when administered either by i.p or orally, but is rapidly eliminated when orally 
administered (<1.5hrs) compared to i.p where its elimination rate is >5hrs (Deiana et al., 
2012). Interestingly, 9-THCV exhibited extensive brain penetration (exceeding plasma 
levels), regardless of the route of administration, meaning it can effectively cross the BBB. 
At 24hrs 9-THCV was no longer detected, suggesting that it exhibits a lack of accumulation 
in brain tissue (Deiana et al., 2012). Altogether these features, along with evidence collected 
in this study, support 9-THCV as a neuroprotective agent, however clearly more data is 
needed, especially to assess 9-THCVs safety in chronic dosing and whether this compound 
exhibits tolerance with long term use. 
 
∆9-THCA is ∆9-THCs acidic precursor and competition binding assays revealed that this 
compound was unable to achieve displacement of [3H]-CP55,940 (CB1 and CB2 agonist) up to 
10 µM, suggesting ∆9-THCA exhibits poor affinity for CB1 or CB2 (McPartland et al., 2017). 
Results from this study also showed that ∆9-THCA has little efficacy at these receptors as it 
exhibited no inhibition of forskolin mediated cAMP, compared to ∆9-THC which acted as an 
agonist in this assay. Our search revealed that ∆9-THCA had anti-inflammatory effects 
improved neural viability in a model of Huntington’s, but interestingly it did not affect the 
survival of dopaminergic neurons in a model of Parkinson’s disease (Moldzio et al., 2012; 
Nadal et al., 2017). In a recent study, Anderson et al., (2019) reported that ∆9-THCA had 
extremely poor brain penetration (an optimistic brain−plasma ratio of 0.15) in both vehicles 
tested. Furthermore, studies have shown that ∆9-THCA has poor stability and rapidly 
decarboxylates to ∆9-THC, bringing into question whether the ability of ∆9-THCA to act as a 
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neuroprotectant in the studies presented here is merely due to nearly unavoidable 
contamination with ∆9-THC (McPartland et al., 2017; Anderson et al., 2019). Overall, these 
data warrant further investigation into ∆9-THCA as a potential neuroprotective and anti-
inflammatory agent, however caution should be advised, and future studies should include 
purity data on ∆9-THCA to enhance robustness of experimental data. 
 
There were no studies identified in this review that looked at the potential neuroprotective 
effects of other cannabinoid varins or their acidic forms such as CBGV, CBGVA, CBDVA, CBCV 
and CBCVA. This may be due to the lack of commercial availability of these compounds due 
to their low concentrations in the plant, costly synthetic production or that these 
compounds are not very stable. CBDA was only used in one study on Huntington’s disease, 
where it had no protective effects. This compound, however, has shown promise in other 
conditions including breast cancer migration, inflammatory pain and nausea (Takeda et al., 
2012; Bolognini et al., 2013; Rock, Limebeer and Parker, 2018), with groups suggesting that 
CBDA is 1000 times more potent at the 5-HT1A receptor than CBD (Bolognini et al., 2013). 
Activation of the 5-HT1A receptor has been shown to be protective both in vitro in 
Parkinsonian models and in vivo in models of hypoxia ischaemia (Miyazaki et al., 2013; Pazos 
et al., 2013). Although Anderson et al., (2019) concluded that CBDA displayed poor brain 
penetration in an oil-based formulation uptake was increased when CBDA was formulated in 
a tween-based vehicle. Authors also found CBDA was anti-convulsant at 10 and 30 mg.kg-1 
displaying greater potency compared to CBD (100 mg.kg-1). These data support CBDA’s 
efficacy in the brain, as well as highlighting its potential as an anticonvulsant. (Anderson et 
al., 2019). Considering these points, CBDA may be also protective in conditions such as 
ischaemic stroke and Parkinson’s disease and warrants further investigation. Recent studies 
have also shown that CBDA, CBGV and CBGA interact with various TRP channel isoforms 
including TRPV1, TRPV2, TRPA1 and TRPM8. Of note, CBGV and CBGA were also potent 
desensitizers of TRPV3 and TRPV4 respectively (De Petrocellis et al., 2012). Whilst the extent 
of the role of TRP channels in neuroprotection has yet to be fully understood, studies have 
shown that these receptors are involved in a wide range of neurological disorders. For 
example, TRPA1 deficient mice were more likely to sustain damage post ischaemia and 
TRPA1 activation in AD may have a crucial role in regulating astrocyte-mediated 
inflammation (Lee et al., 2016; Pires and Earley, 2018). Conversely, TRPV1 activity has been 
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implicated in epilepsy having a role in neuronal excitability and synaptic transmission 
(Nazıroglu, 2015). Therefore, CBDA, CBGV and CBGA interactions at TRP channels may be 
beneficial in conditions that implicate these channels in their pathophysiology. 
Translatability of these data and viability of minor phytocannabinoids as neuroprotectants 
will also rely on understanding and perhaps manipulating their bioavailability and 
pharmacokinetic properties. In a recent systematic review conducted by our group, Millar et 
al., (2018) highlighted discrepancies regarding CBD bioavailability, Cmax, Tmax and half-life 
(t1/2) in humans depending on the route of administration, formulation and whether CBD 
was dosed in a fed or fasted state. That being said, studies conducted in piglets (Garberg et 
al., 2017) and rodents (Long et al., 2012; Hammell et al., 2016) have shown a dose-
dependent relationship between CBD administration and brain and plasma concentrations. 
Limited data extracted by Millar et al., (2018), showed that CBD administration in humans 
also led to dose-dependent increases in plasma concentrations, suggesting the same may 
apply to brain concentrations in man. 
Information on the human metabolites of CBD, ∆9-THC and other phytocannabinoids is 
scarce, with the majority of research has focusing on CBDs extensive first pass metabolism 
and the identification of its urinary metabolites. Of interest, a patent filed by Mechoulam, 
Tchilibon and Fride, (2010) described that CBDs two major metabolites, 7-hydroxy (7-OH) 
CBD and 7-carboxy (7-COOH), are both anti-inflammatory and dose dependently inhibit TNF-
⍺, nitric oxide and ROS. However, this data has yet to be reported in academic studies or 
found to be true of other phytocannabinoids. In addition, the cytochrome P450 (CYP) 
superfamily is responsible for metabolising 60-80% of CNS drugs; 23% by CYP3A4 and 38% 
CYP2C19, both of which CBD is a known substrate (Cacabelos, 2010; Iffland and 
Grotenhermen, 2017). Altogether these findings highlight that there are major gaps in the 
ADME of phytocannabinoids, as well as a lack of identification of metabolites and whether 
they have biological effects. In phase 2 trials, the minor phytocannabinoids presented in this 
review will in all likelihood be used alongside current therapies to see if they can augment 
survival of neurons and/or symptom burden, rather than being used as a single agent. In 
light of the above, it will be essential to consider the interactions that these compounds 
may have when administered in conjunction with conventional drug therapies (where they 
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exist) and to establish potential synergistic or deleterious effects. Looking forward, initial 
ADME data will be incredibly important to ascertain whether these compounds have true 
clinical potential and essential for their subsequent formulating and administration. 
Conclusions 
 
This review aimed to collate and summarise all current data on the neuroprotective 
potential of phytocannabinoids other than ∆9-THC and CBD. Despite the lack of studies 
available in this area, we found that all phytocannabinoids tested displayed neuroprotective 
properties in a range of disorders. CBG and its derivatives displayed significant anti-
inflammatory effects and were particularly effective in Huntington’s disease models. CBDV, 
∆9-THCV and CBC were effective as anti-seizure agents, while CBN displayed antioxidant 
activity and ∆9-THCA had anti-inflammatory effects. CBG and ∆9-THCA, like CBD, mediate 
their anti-inflammatory effects through PPARy. Many of the studies were screening studies 
that conducted no mechanistic probing, suggesting that research into these compounds is 
still in its early stages. Extensive pharmacokinetic and pharmacodynamic data in larger 
mammals is also necessary on these compounds, given that all in vivo studies in this review 
were conducted in mice and rats. This would provide more evidence for the facilitation of 
these compounds as therapies in man. Future studies are required to investigate the full 
neuroprotective potential of these compounds particularly the mechanisms in which they 
mediate their protective effects, as well as exploring whether their combinations may 
enhance their capabilities as neuroprotectants. Whilst we have focused on a select number 
of minor phytocannabinoids, based predominantly on their shared physical and biological 
similarities to CBD, there are over 100 phytocannabinoids and terpenes present in the 
cannabis plant that could potentially display neuroprotective potential. 
 
Nomenclature of Targets and Ligands 
 
Key protein targets and ligands in this article are hyperlinked to corresponding entries 
in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/BPS 
Guide to PHARMACOLOGY (Harding et al., 2018), and are permanently archived in the 
Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019). 
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Table 1a: Summary of included in vitro studies. 
 
Phytocannabinoid Compound Concentration/ 
Incubation 
period 
Neuro Model  Cells used n 
number 






500 nM for 21 days. Huntington’s disease Mouse embryonic stem 
cells (R1 line)/P19 
neurospheres. 
n=3 VCE-003.2 increased CTIP-2 positive cells, promoted neuronal like-
differentiation and significantly larger P19 neurospheres vs vehicle 
treated cells (P<0.01). 
Aguareles J, 




1,5,10 µM (Human T-
cells). 1, 2.5 μM (RAW 
264.7 cells) for 3 days 
post stimulation. 
Autoimmune 
Encephalomyelitis to model 
multiple sclerosis (MS). 





1 µM reduced expression of iNOS in BV2 microglial cells. Antagonists 
AM630 (CB2) and GW9662 (PPARy) blocked these effects.  Prevented T 
cell division at 1 µM and 5 M and inhibition of the release of all 
soluble mediators (T-cells).  
Carrillo 






1- 50 µM (N2a) for 
24hrs 
50 nM-50 µM (HiB5) 
30, 10, 3 M for 6hrs. 







VCE-003.2 improved cell viability (10 and 25 µM) and prevented 
excitotoxicity in N2a cells.  VCE-003.2. reduced the number of cells with 
aggregates (neuroblasts) and improved neuronal viability post serum 
deprivation. 
Diaz-Alonso 










mice treated 15 days 5 
mg.kg i.p VCE-003b) 
Multiple Sclerosis HEK293 cells and 






VCE-003 protected neuronal cells from excitotoxity.  
Reduction in IL-1beta, IL-6, TNF-alpha, PGE2 and MIP-1-alpha in 
microglia (1, 10 and 25 μM) VCE-003 ameliorated MS symptoms 
induced by TMEV. 
 





BV2 cells 5 µM VCE-
003.2 for 21hrs. 
VCE-003.2 (M-213 
cells) Vehicle (0.1% 
DMSO) vs 0.1,0.5, 1 µM 
for 40hrs. 
Parkinson’s disease model 
induced by LPS. 
(Conditioned medium from 
BV2 cells added to M-213 
cells). 
Mouse microglial BV2 
cells. M-213 (striatal 




In BV2 cells, VCE-003.2 significantly decreased TNF-alpha COX-2 and 
iNOS mRNA.  Attenuated TNF-alpha and IL-1beta secreted in medium of 
BV2 cells (5 μM). 
Garcia. C et 
al., 2018 
Cannabigerol MTT assay: 
1,2.5,5,7.5,10,12.5,15,2
0 µM pre-treated 
24hrs. 
NSC-34:Pre-treated 
with 7.5 µM 
Neuroinflammation- 
medium from LPS 
stimulated macrophages. 
NSC-34 motor neurons. n=3 
repeats 
CBG at 2.5 and 7.5 μM increased cell viability approximately 20% 
compared to control. 
CBG pre-treatment inhibited apoptosis and reduced; IL-1β, TNF-alpha, 
INF-Y (NSC-34 motor neurons).  CBG restored decreased Nrf2 levels. 
Gugliandolo 





µM 20 minutes. 
hNAv cells- 1 nM-200 
µM for 100 seconds. 
PTZ Seizures Transverse 
hippocampal slices, SH-








10 µM CBG significantly reduced peak Nav current in SH-SY5Y cells and 
mouse cortical neurons.  CBG was also effective as a low affinity Nav 
channel blocker. 
Hill, A et al., 
2014  
 






0.1,0.5,1, and 5 µM 









VCE.003.2 at 1 and 5 µM attenuated levels of TNF-alpha and IL-1β, 
elevated due to LPS stimulation. 
Rodrígueuz-
Cueto C et 
al., 2018 
Cannabigerol 6hrs-supplementary 
information cannot be 
accessed. 
Huntington’s disease Immortalized striatal 
progenitor cells: 
STHdhQ7/Q7  




CBG dose-dependently activated PPARy. Valdeoliva, S 
et al., 2015 




Neuroprotection Adult neural stem 
cells/progenitor cells 
(NSPC). 





Cannabidivarin 1, 10, 100 µM 30 mins 
after epileptiform 
activity for 30 mins. 
Epilepsy-spontaneous local 
field potentials (LFPs) 
Transverse 
hippocampal slices 





CBDV decreased amplitude and duration of LFPs and increased Mg2+ 
free induced LFPs frequency (>10 µM).  




3, 10, 30 µM 
30-40 mins after 
control readings for 1 
min. 
Epilepsy Human embryonic 
kidney cells (HEK293) 
transfected with 
TRPV1, TRPV2, TRPA1. 
n=4 CBDV was anticonvulsant and TRPV1 antagonist capsazepine blocked 
this effect. 












Neuroprotection Adult Neural stem 
cells/progenitor cells 
(NSPC) 
n=6 CBC raised viability in B27 medium. CBC had no significant effect on 





Cannabinol (CBN) Cannabinol/ 
delta 8 THC 
100, 20, 4, 0.8, 0.16, or 
0 μM for 48hrs. 
 







Cannabinol reduced LDH activity in medium at 20 and 100 μM. At 100 
μM CBN decreased LDH release by 84%. Protective EC50 of CBN was 
determined to be 30 μM in this model. 
Aiken, C et 
al., 2004  
Cannabinol 
(+THC and CBD) 
0.1, 1, 2.5,5 10 µM for 
24hrs. 





expressing cell lines. 
PC12 and HT22 cell 
lines. 
n=3 Cannabinol was shown to be a potent antioxidant. Marsicano G 
et al., 2002  
Tetrahydrocannab
idivarin(∆9-THCV) 
∆9-THCV 0,5 10, 20, 40, 50 M 
applied directly after 
epileptiform activity. 
20 min pre-treatment 
at 10 M. 
In vitro electrophysiology 
(epileptiform bursting)  
Brain slices obtained 
from male and female 
outbred rats. 
n=5 ∆9-THCV (20-50 M) decreased burst incidence, PDS amplitude and 
frequency. The most significant effect was at 50 M.  ∆9-THCV also 
decreased epileptiform burst speed (40 M). ∆9-THCV was found to act 
as a CB1 ligand in receptor binding assays. 
Hill et al., 
2010 
 




∆9-THCA  0.01, 0.1, 1 and 10 M 
for 48hrs 





∆9-THCA had no effect on the survival of dopaminergic neurons, but at 
10 µM led to an increased cell count (123%) and morphology was 










0, 0.5 and 1 µM (∆9-
THCA) N2a cells-
48hrs.0, 0.1-15 µM (∆9-
THCA, CBDA, CBGA in 
HEK-293T cells-6hrs.  1-
10 µM ∆9 THCA 










∆9-THCA increased neuronal cell viability post serum deprivation and 
increased mitochondrial mass. This effect was blocked by a PPARγ 
antagonist GW9662. All cannabinoid acids induced PPARγ 
transcriptional activity in HEK293 cells. 


























Emerging phytocannabinoids did not affect the number of 
dopaminergic neurons. CBG and CBC decreased glutathione levels (0.1, 
1 µM and 1 and 10 µM). 0.1 µM CBDV reduced glutathione levels by 
9.6%, THC, THCA and CBN has no effect. CBDV and CBN decreased 
resazurin reduction at 10 µM (32.9 and 38.9%) and affected PI uptake 
at all concentrations. CBG also affected PI uptake at 0.1 and 10 µM. 
Rosenthaler 










250 nM-10 µM 
Oxytosis assay, 30 
minutes. Energy loss 
assay: 22hrs. Trophic 
factor withdrawal, 
48hrs. 
Alzheimer’s Disease MC65 cells (human 
nerve cell line), Ht22 
cells (mouse 
hippocampal cell line) 





CBG, CBDV, CBC, CBN, THCA prevented oxytosis.  
 
CBG, CBDV, CBC and CBN preserved trophic factors. THCA was toxic to 
MC65 cells at 1 M, however CBDV, CBC, CBN and CBDA prevented 
amyloid toxicity at 100 nM.CBDV, CBG, CBC and CBN (100 nM) 
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10 mg.kg-1 of body weight i.p per 
day until sacrifice. 
Two models of 
Huntington’s 
Disease. 




QA model: VCE-003.2 RotaRod performance, prevented 
neuronal loss, microglial activation and reduced 
astrogliosis. 3NP model: VCE-003.2 improved motor 
deficits, reduced all pro-inflammatory mediator release 







10 mg.kg-1 oral once daily for 3 
days before sacrifice. 
Huntington’s 
Disease. 





VCE-003.2 promoted neurogenesis, increased GFAP 
positive cells and reduced microglial activation.  Mice 
performed better on the RotorRod test drug treated vs 
vehicle. 
Aguarele





Oral 10 mg.kg-1, 20 mg.kg-1, 16hrs 




C57BL/6 F mice, 7-
11 months old 
n=6 mice 
per group 
20 mg.kg-1 partly corrected altered cylinder rearing test 
but poor activity in rotarod and CAA tests. VCE -003.2 
attenuated TNF-a, IL-1b (greatest effect at ^dose missing 








Daily 5 mg.kg-1 i.p for 21 days. Autoimmune 
Encephalomyelitis 
(EAE) to model MS. 
F C57BL/6 mice n= 6 
animals 
per group. 
5 mg.kg-1 of VCE-003 decreased EAE symptoms. VCE-003 
decreased microglial/macrophage activation, reduced 
demyelination, maintained myelin structure and reduced 
axonal damage lesions. Significant decrease in all 
measured inflammatory mediators. 
Carrillo-
Salinas et 





15 days 5 mg.kg-1 i.p VCE-003 
treated 60 days after infection. 
Multiple sclerosis 
(MS) induced by 
TMEV. 
SJL/J mice n=12 Clinical score (0-5) was significantly improved with VCE-
003 treatment. VCE-003 completely recovered motor 







10 mg.kg-1 i.p 16hr post LPS and 




M C57BL/6 mice n=4-6 
subjects 
per group. 
VC-003.2 prevented nigrostriatal neuronal loss and 
reduced microgliosis. Elevation in iNOS was decreased 




Cannabigerol  50-200 mg.kg-1 i.p 1hr before PTZ 
seizures. 
PTZ seizure model 
(85 mg.kg i.p). 
M Wistar Kyoto rats n=72 CBG had no effect on seizure severity, incidence or 
timing and did not alter animal mortality. CBG displayed 
no anti-convulsant effects. 





10 mg.kg-1 i.p animals 60 days old 










In SOD1 mice, VCE-003.2 delayed disease progression 
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4 i.p injections every 24hrs at a 
dose of 10 mg.kg-1. for 6 weeks (4 
weeks after birth to 10 weeks). 
Huntington’s 
disease induced by 
3NP/R6/2 variant 
mice. 
16 week old M 
C57BL/6 mice/ 4-10 




CBG improved motor activities, prevented neuronal loss, 
increased GFAP staining and decreased Iba-1 staining.  
CBG downregulated Huntington associated genes and 
decreased inflammatory mediators. 
Valdeoliv








Pre-treatment Vehicle vs 400 
mg.kg-1 CBDV oral for 3.5 hrs. 
Seizures induced 




(3/4 weeks old). 
n=51 400 mg.kg-1 CBDV significantly decreased seizure severity 
and increased latency to first signs of seizure. CBDV did 







50, 100, 200 mg.kg-1 i.p injection 
1hr/ 30 mins before induced 
seizures. 400 mg.kg oral gavage 
13.5/3.5hr before i.p PTZ. 
Epilepsy (mES 
seizures; 30 mA, 
100 Hz for 200 ms 
or generalized 
seizures 85 mg.kg 
PTZ injected i.p. 
F/M adult Wistar 
Kyoto rats. Non-
Agouti (DBA/) mice 
3-4 weeks, ICR (CD-








200 mg.kg-1 CBDV- 90% of mice remained seizure free. In 
rats, CBDV significantly decreased PTZ seizure severity 
and rodent mortality (200 mg·kg-1) and delayed seizure 
onset. On co-administration experiments, 2.9 % of rats 
(n=7) exhibited a fatal reaction to CBDV administration. 
 
Hill et al., 
2012  
Cannabidivarin 
(only data from 
purified CBDV is 
reported here) 
1hr pre-treatment 50, 100, 200 
mg.kg-1 i.p (rats) 10-200 mg.kg-1 
i.p (mice). 




M Wistar Kyoto 
rats, M MF1 mice, 




CBDV significantly affected observed seizure severity >50 
mg.kg-1. Mortality was reduced by CBDV administration 
and suppressed seizure activity (100 mg.kg-1) 




2, 20, 100 mg.kg-1 vs vehicle 
control, daily i.p for 14 
consecutive days. 




n=70 20 mg.kg-1 CBDV improved motor learning ability. 
Brain weight was increased with CBDV treatment. CBDV 
had no effect on GPR55 levels and neurotrophin levels. 
Vigil, D et 
al., 2018  
Cannabidivarin 
(96.4% CBDV, 3.6 
% CBD) (started 
on postnatal day 
28, lasting until 
day 67) 
0.2, 2, 20, 200 mg.kg-1 i per day 
i.p initiated postnatal day (PND) 
28 until PND 67.  
Rett syndrome 
model; (WT vs 








2-200 mg.kg-1 per day CBDV reduced tremors, 0.2 mg.kg-
1 per day was ineffective. CBDV reduced hind limb 
clasping but again not at the lowest dose tested. CBDV 
improved breathing and gait abnormalities, reduced 
total symptom score and improved neurological motor 
deficits.  
Zamberle




CBC 0.01 mL/g 25, 50,75 mg.kg-1 i CBC 
(mice), 1.0 mL/kg, 10-75 mg.kg-1 i 
CBC (rats) i.p for 1hr prior to 
electroshock. 
Electroshock 
seizure test; 50 mA 
intensity for 0.2 
seconds. 








CBC/THC had no effect on tonic hindlimb extension. CBC 
did not alter latency. CBC (lowest dose) shortened the 
duration of extension. All doses of CBC depressed motor 





Cannabinol (CBN) CBN 5mg.kg.day subcutaneous pouch 




(ALS) SOD1 model. 
M Tg (SOD1-G93A) 
2Gur (11) mice. 
n=18 Motor abnormalities were delayed by CBN vs vehicle. 
No significant difference for PaGE test assessment or the 
age at which animals reached end stage. 
Weydt et 
al., 2005  
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∆9-THCV 2 mg.kg-1 i.p for 14 days. Parkinson’s 
Disease (by 6-
hydroxytryptamine
-6-HT) or LPS. 
M Sprague-Dawley 




THCV improved motor activities, reduced neuronal loss 
and reduced microglial activation. THCV was able to 





∆9-THCV 0.025, 0.25, 2.5 mg.kg-1 i.p 
+vehicle prior to initiating 
seizures. 
Seizures induced 
by 80 mg.kg PTZ. 
M Wistar rats  64 rats in 
total; n=16 
per group. 
Median seizure severity, duration, progression or latency 
was unaffected by any dose of THCV. 33% of animals 
exhibited a complete absence of seizures at a dose of 
0.25 mg.kg-1 THCV. 





∆9-THCA 20.mg.kg-1 i.p 30 mins before 
3NPA, every 24hrs for 4 days. 
Huntington’s 
disease (3 NPA 
model). 
M C57BL/6 mice n=70; 9 
animals 
per group. 
THCA improved hindlimb dystonia and locomotor 






This article is protected by copyright. All rights reserved. 
Table 2: Summary of the conditions where emerging cannabinoids have been studied. A tick or cross represents whether a cannabinoid 












Huntington’s   - -  X -   PPARγa 
Multiple Sclerosis  - - - - - - 
Autoimmune 
Encephalomyelitis 
 PPARγ/CB2a - - - - - - 
Parkinson’s  PPARγa - - - -   
Neuroinflammation 
/neuroprotection 
    -   
Epilepsy/seizure X  TRPV1 a  - -   - 
Amyotrophic 
sclerosis (ALS) 
 - -  - - - 
Oxidative stress - - -  - - - 
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a Some of the compounds neuroprotective effects were mediated by this receptor, but no other receptors were probed. 
Rett syndrome -  - - - - - 
Alzheimer’s disease     - - - - 
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